Evidence map›Paper›PMID 41972010›Full record

ArticleNAR genomics and bioinformatics2026

Lancet2: Improved and accelerated somatic variant calling with joint multi-sample local assembly graphs.

Rajeeva Lochan Musunuri, Bryan Zhu, Wayne E Clarke, William Hooper, Timothy Chu, Jennifer Shelton, André Corvelo, Dickson Chung, Shreya Sundar, Adam M Novak and 4 more

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rajeeva Lochan MusunuriNew York Genome Center, New York, NY, United States.ORCID https://orcid.org/0000-0001-5671-1766
Bryan ZhuNew York Genome Center, New York, NY, United States.
Wayne E ClarkeNew York Genome Center, New York, NY, United States.
William HooperNew York Genome Center, New York, NY, United States.
Timothy ChuNew York Genome Center, New York, NY, United States.
Jennifer SheltonNew York Genome Center, New York, NY, United States.ORCID https://orcid.org/0000-0002-3756-5270
André CorveloNew York Genome Center, New York, NY, United States.
Dickson ChungUC Santa Cruz Genomics Institute, University of California, Santa Cruz, CA, United States.
Shreya SundarUC Santa Cruz Genomics Institute, University of California, Santa Cruz, CA, United States.
Adam M NovakUC Santa Cruz Genomics Institute, University of California, Santa Cruz, CA, United States.
Benedict PatenUC Santa Cruz Genomics Institute, University of California, Santa Cruz, CA, United States.ORCID https://orcid.org/0000-0001-8863-3539
Michael C ZodyNew York Genome Center, New York, NY, United States.
Nicolas RobineNew York Genome Center, New York, NY, United States.ORCID https://orcid.org/0000-0001-5698-8183
Giuseppe NarzisiNew York Genome Center, New York, NY, United States.ORCID https://orcid.org/0000-0003-1118-8849

Funding

Advanced development of Lancet, an emerging tool for complex variant calling in cancer genomicsU01CA253405 · NCI · NEW YORK GENOME CENTER · PI NARZISI, GIUSEPPE · 2021 to 2023
$1.5M
NCI NIH HHS U01 CA253405
6 · The paper itself

Abstract

Here, we present Lancet2, an open-source somatic variant caller designed to improve detection of small variants in short-read sequencing data. Lancet2 introduces significant enhancements, including: (i) Improved variant discovery and genotyping through partial order multiple sequence alignment of assembled haplotype contigs, and re-alignment of sample reads to the best supporting allele. (ii) Optimized somatic variant scoring with explainable machine learning models, leading to better somatic filtering throughout the sensitivity scale. (iii) Integration with Sequence Tube Map for enhanced visualization of variants with aligned sample reads in graph space. When benchmarked against enhanced two-tech truth sets generated using high-coverage short-read (Illumina) and long-read (Oxford Nanopore) data from four well characterized matched tumor/normal cell lines, Lancet2 outperformed other industry-leading tools in variant calling performance, especially for InDels. In addition, significant runtime performance improvements were observed compared to Lancet1 (∼10× speedup and 50% less peak memory usage), and most other state-of-the-art somatic variant callers (at least 2× speedup with eight cores or more), making Lancet2 an ideal tool for accurate and efficient somatic variant calling.

Indexed as

Genetic VariationHigh-Throughput Nucleotide SequencingSequence Analysis, DNASoftwareAlgorithmsHaplotypesHumansSequence Alignment

Identifiers

PMID41972010
PMCPMC13064521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.